[{"address1": "490 Arsenal Way", "address2": "Suite120", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 231 0700", "website": "https://www.c4therapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 110, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew J. Hirsch M.B.A.", "age": 54, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1081125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth C. Anderson M.D., Ph.D.", "age": 74, "title": "Co-Founder, Independent Director & Member of Scientific Advisory Board", "yearBorn": 1951, "fiscalYear": 2024, "totalPay": 45000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kendra  Adams", "title": "Chief Financial Officer and Head of Corporate Affairs & Treasurer", "fiscalYear": 2024, "totalPay": 711215, "exercisedValue": 0, "unexercisedValue": 50296}, {"maxAge": 1, "name": "Dr. Leonard M. J. Reyno M.D.", "age": 63, "title": "Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 837480, "exercisedValue": 0, "unexercisedValue": 8625}, {"maxAge": 1, "name": "Dr. Nathanael S. Gray Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Mossler", "age": 51, "title": "Chief Accounting Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paige  Mahaney Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Courtney  Solberg", "title": "Senior Manager of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly A. Schick", "age": 45, "title": "Chief People Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Isabel  Chiu Ph.D.", "title": "Senior Vice President of Strategic Alliances & Business Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.71, "open": 1.77, "dayLow": 1.725, "dayHigh": 1.8686, "regularMarketPreviousClose": 1.71, "regularMarketOpen": 1.77, "regularMarketDayLow": 1.725, "regularMarketDayHigh": 1.8686, "payoutRatio": 0.0, "beta": 2.95, "forwardPE": -1.4145042, "volume": 821298, "regularMarketVolume": 821298, "averageVolume": 1622696, "averageVolume10days": 988900, "averageDailyVolume10Day": 988900, "bid": 1.78, "ask": 1.85, "bidSize": 5, "askSize": 5, "marketCap": 176384240, "fiftyTwoWeekLow": 1.085, "fiftyTwoWeekHigh": 3.65, "allTimeHigh": 51.21, "allTimeLow": 1.06, "priceToSalesTrailing12Months": 5.8583846, "fiftyDayAverage": 2.2212, "twoHundredDayAverage": 2.13645, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 45963240, "profitMargins": 0.0, "floatShares": 61737392, "sharesOutstanding": 96914418, "sharesShort": 7379826, "sharesShortPriorMonth": 7172653, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0761, "heldPercentInsiders": 0.07196, "heldPercentInstitutions": 0.73792, "shortRatio": 4.4, "shortPercentOfFloat": 0.0805, "impliedSharesOutstanding": 96914418, "bookValue": 2.082, "priceToBook": 0.87415946, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -119081000, "trailingEps": -1.67, "forwardEps": -1.28667, "enterpriseToRevenue": 1.527, "enterpriseToEbitda": -0.393, "52WeekChange": -0.4925816, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 1.82, "targetHighPrice": 20.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.85714, "targetMedianPrice": 7.0, "recommendationMean": 1.125, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 191884000, "totalCashPerShare": 1.98, "ebitda": -117042000, "totalDebt": 61463000, "quickRatio": 5.52, "currentRatio": 5.755, "totalRevenue": 30108000, "debtToEquity": 39.806, "revenuePerShare": 0.423, "returnOnAssets": -0.23196, "returnOnEquity": -0.59981, "grossProfits": -81663000, "freeCashflow": -54987124, "operatingCashflow": -94481000, "revenueGrowth": -0.269, "grossMargins": -2.71234, "ebitdaMargins": 0.0, "operatingMargins": -2.10855, "financialCurrency": "USD", "symbol": "CCCC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "C4 Therapeutics, Inc.", "longName": "C4 Therapeutics, Inc.", "twoHundredDayAverageChange": -0.31645, "twoHundredDayAverageChangePercent": -0.14811954, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-02", "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601645400000, "postMarketChangePercent": -1.0604452, "postMarketPrice": 1.8007, "postMarketChange": -0.019300103, "regularMarketChange": 0.11, "regularMarketDayRange": "1.725 - 1.8686", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1622696, "fiftyTwoWeekLowChange": 0.735, "fiftyTwoWeekLowChangePercent": 0.67741936, "corporateActions": [], "postMarketTime": 1770424793, "regularMarketTime": 1770411601, "exchange": "NMS", "messageBoardId": "finmb_321572356", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 6.43275, "regularMarketPrice": 1.82, "marketState": "CLOSED", "fiftyTwoWeekRange": "1.085 - 3.65", "fiftyTwoWeekHighChange": -1.83, "fiftyTwoWeekHighChangePercent": -0.50136983, "fiftyTwoWeekChangePercent": -49.25816, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.67, "epsForward": -1.28667, "epsCurrentYear": -1.52, "priceEpsCurrentYear": -1.1973685, "fiftyDayAverageChange": -0.40119994, "fiftyDayAverageChangePercent": -0.18062305, "displayName": "C4 Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]